Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSRIs plus Shugan Jieyu for depression (multicenter randomized double-blind trial)
ChiCTR2000041328Phase 4Recruiting
- Sponsor
- Shandong Mental Health Center
- Start
- Dec 2020
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escitalopram and Shugan Jieyu in major depressive disorder (MDD) (3 arms), sponsored by Shandong Mental Health Center. Primary endpoint: Reduction rate of Hamilton Depression Rating Scale after 6 weeks of treatment. Started Dec 2020; status: recruiting.
02
Drugs
escitalopramShugan Jieyu
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2000041328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041328.